Levolet is owned by Genus Lifesciences.
Levolet contains Levothyroxine Sodium.
Levolet has a total of 2 drug patents out of which 0 drug patents have expired.
Levolet was authorised for market use on 06 June, 2003.
Levolet is available in tablet;oral dosage forms.
The generics of Levolet are possible to be released after 23 March, 2038.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10231931 | GENUS LIFESCIENCES | Thyroid hormone oral dosage forms and methods of using the same |
Mar, 2038
(14 years from now) | |
US10406108 | GENUS LIFESCIENCES | Thyroid hormone oral dosage forms and methods of using the same |
Mar, 2038
(14 years from now) |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 06 June, 2003
Treatment: NA
Dosage: TABLET;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic